CARVKTI: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

Grants and Contracts Details

StatusActive
Effective start/end date11/8/2411/8/26

Funding

  • Janssen Research and Development LLC: $2.00